FDA，戈特利布，面对真实世界的证据。

Q4 Medicine

Managed Care Pub Date : 2019-03-01

Richard Mark Kirkner

{"title":"FDA，戈特利布，面对真实世界的证据。","authors":"Richard Mark Kirkner","doi":"","DOIUrl":null,"url":null,"abstract":"Here we are in early 2019, and how quickly and firmly the FDA and the pharmaceutical industry will embrace RWE and its raw material, real-world data (RWD), remains an open question. If that embrace is ever to get beyond gestures and lip service, the FDA will need to change its rules and culture.","PeriodicalId":39329,"journal":{"name":"Managed Care","volume":"28 3","pages":"13-16"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FDA, Gottlieb Get Real About Real-world evidence.\",\"authors\":\"Richard Mark Kirkner\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Here we are in early 2019, and how quickly and firmly the FDA and the pharmaceutical industry will embrace RWE and its raw material, real-world data (RWD), remains an open question. If that embrace is ever to get beyond gestures and lip service, the FDA will need to change its rules and culture.\",\"PeriodicalId\":39329,\"journal\":{\"name\":\"Managed Care\",\"volume\":\"28 3\",\"pages\":\"13-16\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Managed Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Managed Care","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

现在是2019年初，FDA和制药行业将以多快的速度和多坚定的态度接受RWE及其原材料——真实世界数据(RWD)，这仍然是一个悬而未决的问题。如果这种拥抱超越了姿态和口头上的承诺，FDA将需要改变其规则和文化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

FDA, Gottlieb Get Real About Real-world evidence.

Here we are in early 2019, and how quickly and firmly the FDA and the pharmaceutical industry will embrace RWE and its raw material, real-world data (RWD), remains an open question. If that embrace is ever to get beyond gestures and lip service, the FDA will need to change its rules and culture.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Managed Care Medicine-Health Policy

CiteScore

0.30

自引率

0.00%

发文量